Group in China up to three retractions, ostensibly for three different reasons

A group of researchers at Harbin Medical University in China has had a third paper retracted, making for a tale of three notices.

The first retraction appeared in April 2017 as one of more than 100 from Tumor Biology for fake peer review.

The second, for “Functions as a Tumor Suppressor in Osteosarcoma by Targeting Sox2,” was from the International Journal of Molecular Sciences, an MDPI title, in 2018:

Experimental results from [1] were found to be unreliable. In particular, the authors have attempted to replicate the real-time PCR and Western blot experiments but were not able to obtain the same results. All of the authors have agreed to the retraction of the paper [1], which will thus be marked online as retracted. The International Journal of Molecular Sciences is a member of the Committee on Publication Ethics (COPE) and takes very seriously the responsibility to enforce strict ethical policies and standards.

The most recent retraction, which appeared on March 13 in PLOS ONE, was for apparent image duplication:

After publication of this article [1] concerns were raised about results reported in Figs 3 and 5:

  • There are similarities between the 24h panels of MG-63 cells and U2OS cells in Fig 3A.
  • In Fig 3B, there are similarities between the “untreated” and “scramble” panels for both the MG-63 and U2OS cells, as well as a repeated section in the “miR-124 inhibitor” panels for both the MG-63 and U2OS cells.
  • In Fig 3C, the “untreated” panel for the MG-63 cells is repeated in the “scramble” panel for U2OS cells. There is also a repeated section in the “miR-124 mimic” panels for both cells.
  • In Fig 5C, there is a repeated section in the panels labeled “Rac1” and “Rac1+miR-124.”

The authors noted that the original data underlying Figs 3 and 5 are no longer available. The authors requested retraction due to concerns about the reliability of the data reported in the article.

In light of the above concerns, the authors and PLOS ONE Editors retract this article.

The authors agreed with the retraction.

The paper has been cited 40 times, according to Clarivate Analytics’ Web of Science. Chenglin Yang, who is corresponding author of the PLOS ONE paper, first author of the IJMS paper, and last author of the Tumor Biology paper, did not respond to a request for comment.

Of course,”were found to be unreliable” — from the IJMS notice — and image duplication are not mutually exclusive, although it would be good to know what led the authors, or the journal, to the “unreliable” claim.

As we’ve been showing since 2011, retraction notices can vary greatly even when they’re apparently describing the same kinds of problems. Retraction notices do not always — or even often — tell the whole story, and journals frequently decide to highlight problems that are easiest to demonstrate.

Like Retraction Watch? You can make a tax-deductible contribution to support our growth, follow us on Twitter, like us on Facebook, add us to your RSS reader, sign up for an email every time there’s a new post (look for the “follow” button at the lower right part of your screen), or subscribe to our daily digest. If you find a retraction that’s not in our database, you can let us know here. For comments or feedback, email us at team@retractionwatch.com.

One thought on “Group in China up to three retractions, ostensibly for three different reasons”

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.